EDIT(EDIT)
EDIT
Next earnings: Aug 11, 2026
Signal
Mixed1↑1↓
PRICE
Prev Close
2.85
Open
2.86
Day Range2.57 – 2.88
2.57
2.88
52W Range1.43 – 4.54
1.43
4.54
38% of range
VOLUME & SIZE
Avg Volume
1.6M
FUNDAMENTALS
P/E Ratio
-2.3x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
2.07
High vol
Performance
1D
-8.07%5D
-15.76%1M↓
-21.79%3M
+50.57%6M
+0.77%YTD
+27.80%1Y↑
+73.51%Best: 1Y (+73.51%)Worst: 1M (-21.79%)
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +8% YoY · 99% gross marginValuation
FAIR
P/E not availableHealth
WEAK
CR 3.2 · FCF negativeLean Bullish
Key MetricsTTM
Market Cap$256.51M
Revenue TTM$38.69M
Net Income TTM-$108.95M
Free Cash Flow-$141.09M
Gross Margin98.8%
Net Margin-281.6%
Operating Margin-297.5%
Return on Equity-677.4%
Return on Assets-73.0%
Debt / Equity16.33
Current Ratio3.22
EPS TTM$-1.11
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
3 strong3 concern
50/100Liquidity
3.22Strong
Leverage
16.33Concern
Coverage
100.6xStrong
ROE
-677.4%Concern
ROIC
-93.0%Concern
Cash
$147MStrong
ANALYST COVERAGE23 analysts
BUY
▲ +90.8%upside to target
L $4.00
Med $5.00consensus
H $6.00Stock Health
Composite Score
4 of 5 signals bullish
7/10
Technicals
●
✓RSI RangeRSI 58 — Bullish momentum
Volume
●
✗Volume FlowDistribution — institutional selling
Fundamentals
●
✓Last EarningsBeat estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 3.22 — healthy liquidity
Upcoming Events
EEarnings ReportMay 18, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 89 days
PDividend PaymentAug 28, 2026
In 103 days
FinancialsFull statements →
Technicals
Technical SetupBULLISH
Technicals →Trend
▲ RallyDeath Cross · 50D trails 200D by 8.7%
+9.1% vs SMA 50 · -0.4% vs SMA 200
Momentum
RSI58.3Positive momentum, not extended
MACD+0.15Above zero — bullish momentum · compressing
Market Position
Price Levels
52W High
$4.54+73.2%
Current
$2.62
EMA 50
$2.57-1.9%
EMA 200
$2.57-2.0%
52W Low
$1.43-45.4%
52-Week RangeMid-range
$1.4338th %ile$4.54
Squeeze SetupVolume-based
Distribution PressureDistribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
20-Day Money Flow
Acc days:1
Dist days:2
Edge:+1 dist
Volume Context
Avg Vol (50D)1.6M
Recent Vol (5D)
1.1M-30%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 8 analysts
Analyst revisions:EPS↓ Revised DownRevenue↑ Revised Up
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $24.1M $18.9M–$34.7M | — | -$1.98 | — | ±5% | High8 |
FY2026(current) | $14.0M $8.3M–$22.8M | ▼ -42.1% | -$1.00 | — | ±36% | High8 |
FY2027 | $12.8M $11.9M–$13.6M | ▼ -8.8% | -$0.95 | — | ±46% | High7 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryEDIT
Last 8Q
+2.6%avg beat
Beat 5 of 8 quartersMissed 3↑ Estimates rising-19%
Q3'24
+1%
Q4'24
-41%
Q1'25
+16%
Q2'25
-54%
Q3'25
+26%
Q4'25
+78%
Q1'26
+13%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightAnalyst Activity
All ratings →No recent activity
Evercore ISIOutperform
Nov 6
UPGRADE
Bank of America Sec…Buy
Aug 8
UPGRADE
Morgan StanleyUnderweight → Equal-Weight
May 8
UPGRADE
Cantor FitzgeraldOverweight → Neutral
Oct 17
DOWNGRADE
Piper SandlerBuy
Sep 29
UPGRADE
Raymond JamesOutperform
Jun 12
UPGRADE
OppenheimerOutperform → Perform
Nov 18
DOWNGRADE
Credit SuisseNeutral
Nov 18
DOWNGRADE
Insider Activity
SEC Filings →0 Buys/6 SellsNet Selling
O'neill Gilmore NeilDir
$11K
Mar 3
SELL
Parison AmyCFO
$957
Mar 3
SELL
Burkly LindaEVP, CHIEF SCI…
$2K
Mar 3
SELL
Burkly LindaEVP, CHIEF SCI…
$2K
Dec 3
SELL
O'neill Gilmore NeilDir
$12K
Dec 3
SELL
Parison AmyCFO
$993
Dec 3
SELL
Financials
INSTITUTIONAL OWNERSHIP
1
BlackRock, Inc.
9.3M▼2
RENAISSANCE TECHNOLOGIES LLC
4.0M▲3
GEODE CAPITAL MANAGEMENT, LLC
2.3M▲4
STATE STREET CORP
2.1M▲5
Nuveen, LLC
2.0M▲6
JPMORGAN CHASE & CO
1.9M▲7
D. E. Shaw & Co., Inc.
1.9M▲8
Opaleye Management Inc.
1.9M▲News & Activity
EDIT News
About
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Cynthia Collins
Website
Tom LoveVice President of People
Brieana BuckleySenior Vice President of Development and Program Leadership
Gilmore O'NeillPresident, Chief Executive Officer & Director
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
EDIT◀ | $2.62 | -8.07% | $257M | — | +2539.5% | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.96% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.79% | — | 50.3 | +342212.6% | -4085.6% | 1500 |